Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

McMaster University

$105,000.00

Generating an Off the Shelf T-Cell Therapy Using Covalent Immune Recruiters

EF 2022-23

Résumé
T cells present a powerful tool for cancer treatment given their ability to circulate throughout the body and "seek out and destroy" tumor deposits. The infusion of cancer patients with tumor-specific T cells is now a clinically proven treatment for cancer with four currently available. Accessibility to this promising therapeutic is limited by the requirement for the per-patient and per-target manufacturing of therapeutic T cells. Conventional synthetic antigen receptors (SARs) are rigid and typically limited to one tumor target. Given the vast number of potential targets this introduces significant timing, logistic and cost challenges when applying this approach broadly. Our program seeks to overcome these challenges by creating an on demand "off-the-shelf" solution. We propose the use of Universal SARs that can be programmed with target specificity after the engineered T cells are manufactured. A universal SAR employs an acceptor moiety which binds a molecular adapter that links the T cell to the tumor. By creating a library of adapters, a T cell engineered with a single universal SAR can be directed against multiple tumor targets. We have developed molecular adapters, termed covalent immune recruiters (CIRs), that chemically link immune receptors to cancer cells. Our grand vision is an off-the-shelf engineered T cell that is purpose-built for on demand CIR-mediated targeting and a library of CIRs directed against an array of tumor targets to yield an affordable personalized therapy. In our initial studies we have shown that we can redirect several different types of universal SAR T-cells to different tumor targets using several different CIRs. Engineering T cells with universal SARs offers the promise of producing a single engineered T cell product that can be programmed in a dynamic fashion to individual tumors, which should keep costs low, as the adapters are far less expensive to produce than engineered T cells and remove barriers to accessibility.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
475473
Name
Serniuck Nickolas
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Generating an Off the Shelf T-Cell Therapy Using Covalent Immune Recruiters
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Biochemistry; Cancer Immunotherapy; Chemical Biology; Chemical Immunotherapy; Engineered T-Cells; Universal Cancer Approaches
Abstract
T cells present a powerful tool for cancer treatment given their ability to circulate throughout the body and "seek out and destroy" tumor deposits. The infusion of cancer patients with tumor-specific T cells is now a clinically proven treatment for cancer with four currently available. Accessibility to this promising therapeutic is limited by the requirement for the per-patient and per-target manufacturing of therapeutic T cells. Conventional synthetic antigen receptors (SARs) are rigid and typically limited to one tumor target. Given the vast number of potential targets this introduces significant timing, logistic and cost challenges when applying this approach broadly. Our program seeks to overcome these challenges by creating an on demand "off-the-shelf" solution. We propose the use of Universal SARs that can be programmed with target specificity after the engineered T cells are manufactured. A universal SAR employs an acceptor moiety which binds a molecular adapter that links the T cell to the tumor. By creating a library of adapters, a T cell engineered with a single universal SAR can be directed against multiple tumor targets. We have developed molecular adapters, termed covalent immune recruiters (CIRs), that chemically link immune receptors to cancer cells. Our grand vision is an off-the-shelf engineered T cell that is purpose-built for on demand CIR-mediated targeting and a library of CIRs directed against an array of tumor targets to yield an affordable personalized therapy. In our initial studies we have shown that we can redirect several different types of universal SAR T-cells to different tumor targets using several different CIRs. Engineering T cells with universal SARs offers the promise of producing a single engineered T cell product that can be programmed in a dynamic fashion to individual tumors, which should keep costs low, as the adapters are far less expensive to produce than engineered T cells and remove barriers to accessibility.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Serniuck, Nickolas
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~